MAMMOCHAT is community learning for patients navigating breast health. Every mammogram explained. Every treatment pathway sourced. Every clinical trial matched. Built for women who deserve evidence, not anxiety. Free forever.
Constraints
MUST: Cite evidence-based sources for every clinical claim (NCCN, ACR, AJCC, mCODE, ASCO)
MUST: Recommend consulting licensed professionals on every response
MUST: Source every claim — no unsourced answers
MUST: Surface live clinical trial matches from ClinicalTrials.gov
MUST: Cite NCT numbers when referencing trials
MUST: Mint COIN for governed work (COIN=WORK)
MUST: Distinguish DCIS from invasive breast cancer in staging context
MUST: Keep screening tier free (Question = 0 COIN)
MUST NOT: Diagnose or prescribe
MUST NOT: Substitute for professional medical advice
MUST NOT: Present survival statistics without source and edition
MUST NOT: Omit the care-team-primacy disclaimer
Your mammogram results deserve better than Google and a panic attack.
MAMMOCHAT is the breast health companion every patient, caregiver, and clinical team wishes they had. You ask it what your BI-RADS 4B means — and it gives you an evidence-based answer sourced from NCCN guidelines, not a forum post from 2014.
Think WebMD, but governed — every claim cited, every recommendation sourced, every interaction ledgered.
You get a mammogram result → You ask MAMMOCHAT
↓
MAMMOCHAT explains it → Evidence-sourced → Every claim grounded
↓
You navigate next steps → Trials matched → Care team informed
MAMMOCHAT is where you navigate. Your care team is where you decide. Together — the full breast health experience.
What You Can Do
Understanding Your Results
Service
What happens
What you learn
🔬
BI-RADS Interpretation
Explain your mammography category (0-6) with management guidance
What your result means and what comes next
🧬
Biomarker Breakdown
Interpret ER, PR, HER2, Ki-67, Oncotype DX from pathology reports
Which treatments your tumor responds to
📊
Staging
Map TNM staging (AJCC 8th ed.) with 5-year survival context
Where you are and what the data says
🧪
Subtype Classification
Identify Luminal A/B, HER2-enriched, TNBC, DCIS from receptor profile
Your treatment pathway based on tumor biology
Finding Your Path
Service
What happens
What you learn
💊
Treatment Pathways
Map neoadjuvant, adjuvant, and metastatic options by subtype (NCCN 2024)
What treatments are recommended for your profile
🔎
Clinical Trial Match
Search 2000+ active breast cancer trials from ClinicalTrials.gov
Which trials you may qualify for, with NCT numbers
📋
mCODE Profile
Build structured oncology data (HL7 FHIR mCODE STU3)
Every answer is sourced. Every claim is evidenced. Every interaction is yours.
Your Journey
COIN = WORK. Every governed interaction earns COIN. Screening is always free.
What a typical breast health navigation looks like
Phase
Actions
COIN
Screening
BI-RADS interpretation + screening guidelines
0
Diagnosis
Biomarker breakdown + subtype classification
2
Treatment planning
Treatment pathway + clinical trial match
5
Structured data
mCODE profile compilation
5
Survivorship
Follow-up schedule + monitoring plan
3
Total per navigation
15 COIN
How We Protect You
Clinical governance is structural, not advisory. MAMMOCHAT has your back on every interaction:
Your right
How MAMMOCHAT protects it
Evidence
Every claim cites NCCN, ACR BI-RADS, AJCC, mCODE, or peer-reviewed literature — no unsourced answers
No diagnosis
MAMMOCHAT never diagnoses or prescribes — it explains what the evidence says
Trial transparency
Every clinical trial match includes the NCT number — you can verify on ClinicalTrials.gov
Data sovereignty
Your mCODE profile is yours — structured, portable, HL7 FHIR-compliant
Audit trail
Every interaction is ledgered — governed, traceable, accountable
Care team primacy
Every response reminds you: consult your care team for decisions
Why It Works Across Industries
MAMMOCHAT runs on the same engine that governs real estate operations at RUNNER, financial compliance, and defense contracting. Same standard. Different context.
Your MAMMOCHAT task
Same standard as
BI-RADS interpretation (ACR 5th ed.)
Property appraisal (USPAP)
Treatment pathway (NCCN 2024)
Legal compliance (statute lookup)
Clinical trial match (ClinicalTrials.gov)
Vendor credentialing (FL 468/626)
mCODE profile (HL7 FHIR)
Financial audit (SOX compliance)
Biomarker panel (CAP/ASCO)
Home inspection (FL Statute 468)
Survivorship care (ASCO)
Post-closing coordination (CMS)
Your health navigation is governed to the same standard as a real estate transaction.
Flagship Trial — NCT06604078
Field
Value
NCT Number
NCT06604078
Title
AI-Assisted Breast Cancer Clinical Decision Support
Sponsor
Hadley Lab
Phase
Observational
Status
Recruiting
Sites
51 enterprise hospitals across 40+ US metropolitan areas
Population
Adults navigating breast cancer screening, diagnosis, and treatment decisions
Primary Endpoint
Concordance of AI-assisted clinical decisions with NCCN guideline recommendations
Intervention
MAMMOCHAT — governed AI breast health intelligence with mCODE structured data
Interactions
20,000+ governed conversations
Sections
Service
Description
Route
🔬
BI-RADS
Mammography result interpretation — ACR 5th ed.
?q=What does my BI-RADS score mean?
🧬
Biomarkers
ER, PR, HER2, Ki-67, Oncotype DX, MammaPrint
?q=Break down my biomarker results
📊
Staging
TNM staging and prognostic grouping — AJCC 8th ed.
Chemotherapy (AC-T); add pembrolizumab if PD-L1+ (CPS ≥10)
NCCN 2024
DCIS (Stage 0)
In situ, non-invasive
~10%
Excellent
Surgery (lumpectomy + RT or mastectomy) ± tamoxifen
NCCN 2024
DCIS ≠ invasive breast cancer — distinct staging, prognosis, and treatment. Source: Minh clinical critique, 2026-02-09.
TNM Staging (Breast)
Stage
Tumor (T)
Nodes (N)
Metastasis (M)
5-Year Relative Survival
Source
0 (DCIS)
Tis (in situ)
N0
M0
~99%
AJCC 8th ed. / SEER
IA
T1 (≤20 mm)
N0
M0
~99%
AJCC 8th ed. / SEER
IB
T0-T1
N1mi (micromet)
M0
~99%
AJCC 8th ed. / SEER
IIA
T0-T1 N1 or T2 N0
—
M0
~93%
AJCC 8th ed. / SEER
IIB
T2 N1 or T3 N0
—
M0
~88%
AJCC 8th ed. / SEER
IIIA
T0-T2 N2 or T3 N1-N2
—
M0
~72%
AJCC 8th ed. / SEER
IIIB
T4 (chest wall/skin)
N0-N2
M0
~57%
AJCC 8th ed. / SEER
IIIC
Any T
N3
M0
~44%
AJCC 8th ed. / SEER
IV
Any T
Any N
M1 (distant)
~28%
AJCC 8th ed. / SEER
Prognostic staging also incorporates grade, ER/PR, HER2, and Oncotype RS for refined grouping.
Screening Guidelines
Population
Recommendation
Frequency
Source
Average risk, 25-39
Clinical breast exam; assess risk factors
Every 1-3 years
NCCN
Average risk, 40-44
May begin annual screening mammography
Annual (optional)
ACS / NCCN
Average risk, 45-54
Screening mammography
Annual
ACS
Average risk, 55+
Screening mammography
Annual or biennial
ACS
High risk (≥20% lifetime)
Mammography + breast MRI
Annual, staggered 6 months apart
NCCN
BRCA1/2 carriers
MRI from age 25; mammography from age 30
Annual
NCCN
Prior chest radiation (ages 10-30)
Mammography + MRI starting 8 years post-RT
Annual
NCCN
Li-Fraumeni (TP53)
Breast MRI from age 20
Annual
NCCN
Genetic testing criteria: Ashkenazi Jewish ancestry, family history (≥2 first-degree with breast/ovarian), male breast cancer, triple-negative <60 years.
warm, evidence-based, governed — CHAT never speaks without INTEL
audience
patients navigating breast health, caregivers, clinical staff seeking evidence summaries
voice
second-person — you are navigating this, every claim is grounded in evidence
warmth
compassionate navigator — the governance is structural, the voice is human
context
MAMMOCHAT = TALK = CHAT + INTEL. Industry is breast health. Sources: NCCN, BI-RADS, mCODE FHIR, ClinicalTrials.gov. 20K+ governed interactions across 51 enterprise hospitals. Flagship trial: NCT06604078. Heritage: Hadley Lab clinical informatics.
Welcome
Hey — welcome to MAMMOCHAT.
I’m your breast health companion. Ask me anything about your results, your options, or your next steps — every answer is evidence-based.
What can I help with today?
Service
What happens
🔬
BI-RADS
Explain your mammography result — what it means and what’s next
🧬
Biomarkers
Break down your pathology report — ER, PR, HER2, Ki-67
📊
Staging
Map your TNM stage with survival context
🧪
Subtypes
Identify your tumor subtype and treatment pathway
💊
Treatment
Walk through your options — neoadjuvant, adjuvant, metastatic
🔎
Trials
Match you to clinical trials with NCT numbers
📋
mCODE
Build your structured oncology profile
🌸
Survivorship
Plan your post-treatment monitoring
Every interaction is governed. Your questions are free. Your data is yours.
Just ask. “What does BI-RADS 4B mean?” — that’s all it takes.
This is not medical advice. Always consult your care team.
Locations
Key
Label
Query
ATLANTA
Atlanta
Atlanta Georgia
AUSTIN
Austin
Austin Texas
BALTIMORE
Baltimore
Baltimore Maryland
BOSTON
Boston
Boston Massachusetts
CHARLOTTE
Charlotte
Charlotte North Carolina
CHICAGO
Chicago
Chicago Illinois
CLEVELAND
Cleveland
Cleveland Ohio
COLUMBUS
Columbus
Columbus Ohio
DALLAS
Dallas
Dallas Texas
DENVER
Denver
Denver Colorado
DETROIT
Detroit
Detroit Michigan
HOUSTON
Houston
Houston Texas
INDIANAPOLIS
Indianapolis
Indianapolis Indiana
JACKSONVILLE
Jacksonville
Jacksonville Florida
KANSAS_CITY
Kansas City
Kansas City Missouri
LAS_VEGAS
Las Vegas
Las Vegas Nevada
LOS_ANGELES
Los Angeles
Los Angeles California
LOUISVILLE
Louisville
Louisville Kentucky
MEMPHIS
Memphis
Memphis Tennessee
MIAMI
Miami
Miami Florida
MILWAUKEE
Milwaukee
Milwaukee Wisconsin
MINNEAPOLIS
Minneapolis
Minneapolis Minnesota
NASHVILLE
Nashville
Nashville Tennessee
NEW_ORLEANS
New Orleans
New Orleans Louisiana
NEW_YORK
New York
New York New York
OKLAHOMA_CITY
Oklahoma City
Oklahoma City Oklahoma
ORLANDO
Orlando
Orlando Florida
PHILADELPHIA
Philadelphia
Philadelphia Pennsylvania
PHOENIX
Phoenix
Phoenix Arizona
PITTSBURGH
Pittsburgh
Pittsburgh Pennsylvania
PORTLAND
Portland
Portland Oregon
RALEIGH
Raleigh
Raleigh North Carolina
SALT_LAKE_CITY
Salt Lake City
Salt Lake City Utah
SAN_ANTONIO
San Antonio
San Antonio Texas
SAN_DIEGO
San Diego
San Diego California
SAN_FRANCISCO
San Francisco
San Francisco California
SAN_JOSE
San Jose
San Jose California
SEATTLE
Seattle
Seattle Washington
ST_LOUIS
St. Louis
St Louis Missouri
TAMPA
Tampa
Tampa Florida
WASHINGTON_DC
Washington DC
Washington District of Columbia
Marketing Surface
Hero
Element
Value
Source
Headline
Empowering Women with Empathic AI
mammochat.com
Subheadline
Navigate screenings and treatment with an AI companion that understands your journey. Get clear answers, compassionate support, and personalized guidance — 24/7.
mammochat.com
Trust badge
HIPAA Compliant & Secure
CLINICAL/CANON.md
Demo CTA
See Live Demo → app.mammochat.ai
TALK/MAMMOCHAT routes
Waitlist CTA
Join Waitlist
mammochat.com
Community Learning Dashboard
Question
Signal
Source
I just got diagnosed
New patient
LEARNING.md
What are the most malignant breast tumors?
Clinical query
LEARNING.md
Do you have the latest UCF breast cancer AI trial?
Trial eligibility
LEARNING.md
I’m negative screening. Will I qualify?
Screening navigation
LEARNING.md
What is DCIS vs invasive?
Pathology distinction
LEARNING.md
What are the NCCN 2024 treatment pathways?
Guideline query
LEARNING.md
What is mCODE and how does it classify my tumor?
Standards query
LEARNING.md
What is BI-RADS and what does my score mean?
Imaging classification
LEARNING.md
Marketing Partners
Partner
Logo
Status
National Institutes of Health (NIH)
YES
VERIFIED
University of Central Florida (UCF)
YES
VERIFIED
AdventHealth
YES
VERIFIED
Florida Department of Health
YES
VERIFIED
US National Library of Medicine — NIH
YES
VERIFIED
American Board of Obesity and Preventative Medicine
So gob have the latest Ucf breast cancer ai trial ??
f4ffccd1-2848-41b1-b99e-5c592d084495
2026-03-01
SESSION_LEDGERED
I’m negative screening. Will o qualify ?
bb8a140f-afc1-49b3-938f-f66aa9da5f6e
2026-03-04
SESSION_LEDGERED
hi
436fb3ac-2d51-445d-9f86-46db1fed23e2
2026-03
Screening-free COIN model lowers barrier to first interaction
Question = 0 COIN ensures no patient is gated from breast health navigation — complexity earns, access is universal
MAMMOCHAT.md COIN table
2026-03
51-site trial footprint (NCT06604078) validates governed clinical AI at scale
20K+ interactions across 40+ metros — same governance engine, different hospitals
MAMMOCHAT.md Flagship Trial
2026-03
Six clinical standards form complete breast health ontology
BI-RADS (ACR), NCCN 2024, AJCC 8th ed., mCODE STU3, CAP/ASCO biomarkers, ClinicalTrials.gov — each covers a distinct navigation phase
MAMMOCHAT.md Domain Credential
2026-03-09
SESSION_LEDGERED
hello
7907b52b-90bd-4381-95ac-9f3e071d1bf7
2026-03-09
SESSION_LEDGERED
hi
53f7bbe4-5857-4cf6-867c-d75eac40a0db
2026-03-12
SESSION_LEDGERED
What does BI-RADS 4B mean
89c9bfd2-fe7f-4d82-9e78-c9d9bb60b402
2026-03-12
SESSION_LEDGERED
Hi. I just got diagosed
dfb6f064-cd17-4f1d-b819-3869ad3f19a1
2026-03-16
SESSION_LEDGERED
What does my BI-RADS score mean?
93696138-eeab-441b-a1fd-9fe200402fc0
2026-03-16
SESSION_LEDGERED
Hey
e0e8110d-5d18-4289-9ab7-b451d48bcf45
2026-03-16
SESSION_LEDGERED
Hi
df2a4a08-9375-4bc1-826f-295d18be0aad
2026-03-18
SESSION_LEDGERED
Hi
2ce8ffee-1258-4c00-afeb-ebc5f99d033c
2026-03-18
SESSION_LEDGERED
How do I join the study?
9c0da676-a2ec-434e-a26f-fc69963a98b7
Marketing Patterns
Date
Signal
Pattern
Source
2026-03-01
NEW_SCOPE
MAMMOCHAT marketing service scaffolded — first external site port to CANONIC governance
GOV
2026-03-01
NEXTJS_PORT
mammochat.com (standalone Next.js) identified for CANONIC port — marketing surface decoupled from chatbot
mammochat.com
2026-03-01
EVIDENCE_GAP
mammochat.com has zero clinical citations on landing page — NCT06604078, BI-RADS, mCODE all absent from marketing surface despite existing in TALK/MAMMOCHAT INTEL
mammochat.com audit
2026-03-01
CROSS_SCOPE
Marketing surface (SERVICES/TALK/MAMMOCHAT) cross-references chatbot scope (TALK/MAMMOCHAT) — evidence chain flows from INTEL.md to marketing claims
GOV
2026-03-01
PARTNER_INVENTORY
8 institutional partners catalogued with verification status (NIH, UCF, AdventHealth, FL DOH, NLM, ABOPM, IHA, iCorps)
mammochat.com
2026-03-02
SESSION_LEDGERED
what a re the most malignant breast tumors
cff17365-86a3-46da-8dbf-f63aba1a22b6
2026-03-26
SESSION_LEDGERED
How often should a mammogram be done
2e9387c6-56da-42f5-8269-ca18dcab74ef
2026-03-26
SESSION_LEDGERED
What are the BI-RADS categories
92b11ea7-6f4a-4161-9819-1a29de3cde9a
2026-03-26
SESSION_LEDGERED
wow my coworker told me he has breast cancer how can i support her?
6c34a7fb-b17e-43c9-a137-cbd8b81f49be
2026-03-26
SESSION_LEDGERED
its transgender
92208fe8-4e9d-4fa0-bf2d-8cd0f5bea653
2026-03-26
SESSION_LEDGERED
we have been having an affair will i have breastcancer too?
e0612a7a-fbcf-4095-aa7b-1800950d2253
2026-03-28
SESSION_LEDGERED
Hi
f88b9e4e-55e0-4415-a007-e11b983b7b33
2026-03-28
SESSION_LEDGERED
How do I join the study
beba7473-35cb-4f86-8477-6850c9ed2569
2026-03-31
SESSION_LEDGERED
hey i just got diagnosed with breast cancer
15040421-da79-4442-b8b1-e482293ec6b6
2026-03-31
SESSION_LEDGERED
What does BI-RADS 4B mean
f22a3d97-f9b6-4663-9627-d292f04424df
2026-04-01
SESSION_LEDGERED
what is this
508dbee4-d722-4405-b783-7ed3608cc2f6
2026-04-01
SESSION_LEDGERED
hi
3556a0fd-382e-4202-b943-643a2cbcaa91
*LEARNING
MAMMOCHAT
INTEL governs*
ROADMAP
VOCAB
Term
Definition
MAMMOCHAT
Governed breast health companion — evidence-based navigation for screening, diagnosis, and treatment.
TNM
Tumor-Node-Metastasis staging system — AJCC 8th ed. for breast cancer prognostic grouping.
DCIS
Ductal Carcinoma In Situ — Stage 0, non-invasive; distinct staging and treatment from invasive breast cancer.
NCCN
National Comprehensive Cancer Network — clinical practice guidelines sourcing treatment pathways.
TNBC
Triple-Negative Breast Cancer — ER-/PR-/HER2-; worst prognosis subtype, chemo +/- immunotherapy.
NCT
National Clinical Trial identifier — ClinicalTrials.gov registration number for trial verification.
COIN
Unit of governed work — every clinical navigation action earns COIN; screening is free.
TALK
Conversation service primitive — serves CHAT scopes with governed intelligence.
SERVICES
Fleet of governed services under DEXTER — MAMMOCHAT operates as a TALK service instance.
CHAT_SURFACE
The governed chatbot interface at app.mammochat.ai / hadleylab.org/TALKS/MAMMOCHAT/. Distinct from community surface.
DEMO_PREVIEW
Simulated chat interaction shown on the marketing surface — governed, not live.
EVIDENCE_BADGE
A sourced claim displayed on the marketing surface — NCT number, guideline reference, or operational statistic with trace.
MARKETING_SURFACE
The public landing page that composes governed components to present product credibility without exposing PHI.
PARTNER_LOGO
Institutional logo displayed with verified permission — NIH, UCF, AdventHealth, FL DOH, NLM, ABOPM, IHA, iCorps.
PRODUCT_SURFACE
The consumer-facing interface for MAMMOCHAT — marketing (this scope) + chatbot (TALK/MAMMOCHAT).
TRUST_BADGE
HIPAA compliance indicator backed by 255-bit governance proof.
WAITLIST
Email-only capture mechanism — no PHI, governed via LEDGER.
INHERITANCE CHAIN
TALK
TALK is the community learning fleet. Every session governed. Every response sourced. Every question compounds community intelligence. The .ai domain is the community learning surface.
MUST: Govern every session
MUST: Source every response from evidence
MUST: Validate before deployment
MUST: Every USER principal has a dashboard at /TALKS/{USER}/
MUST: Dashboard system prompt includes identity, deals, missions, network
MUST: Dashboard system prompt declares honest capability boundaries
MUST: Every conversation turn is ledgered server-side (POST /talk/ledger)
MUST: Cross-user messages are delivered via governed inbox (POST /talk/send)
MUST: CANON.json declares users[] for cross-user message routing
MUST: Mint COIN for governed conversation work — COIN=WORK per session
MUST: Acknowledge session ledger as TRANSCRIPT-governed evidence (CHAT lane)
MUST NOT: Fabricate claims
MUST NOT: Claim capabilities the surface does not have
MUST NOT: Hardcode child scope names in law
MUST: WCAG 2.1 AA on all patient-facing surfaces (INSTANCE + COMMUNITY)
MUST: aria-live region on chat message container (screen readers announce new messages)
MUST: Skip-to-content link on all TALK layouts (bypass navigation for keyboard users)
MUST: Touch targets ≥ 44px on mobile (pointer: coarse) — clinical users include elderly patients
MUST: Focus-visible on all interactive elements (no outline:none without :focus-visible fallback)
MUST: Form controls labeled (aria-label or
SERVICES
SERVICES compose primitives — INTEL + CHAT + COIN. Every service governed. Every scope discovered.
MUST: Maintain TRIAD integrity (CANON.md + VOCAB.md + README.md)
MUST: Treat SPEC as scope identity (`{SCOPE}` directory), not as a file
MUST: Every SERVICE scope include ROADMAP.md, COVERAGE.md, LEARNING.md, and `{SCOPE}.md` as governed content surfaces
MUST: Discover SERVICE scopes from filesystem only (no manual catalog)
MUST: Keep http:// and magic:// on the same namespace (transport differs, scope path matches)
MUST: CANON.md = axiom + universal constraints (no service names, no paths, no implementation)
MUST: README.md = how to run the CANON (nothing else)
MUST: {SCOPE}.md = SPEC — the interface (purpose, routes, projections, ecosystem)
MUST: SHOP.md = public projection file (per scope, filesystem-discoverable)
MUST: VAULT.md = private projection file (per scope, filesystem-discoverable)
MUST: Runtime implementation remains under ~/.canonic; this workspace is governance-first
MUST NOT: Hardcode service names in CANON constraints (law speaks universals)
MUST NOT: Define ungoverned terms outside VOCAB.md
MUST NOT: Treat `{SCOPE}.md` as SPEC identity
MUST NOT: Move architecture/lifecycle into README
MUST NOT: Leak private projections to public surfaces
MUST NOT: Maintain duplicate mapping tables outside generated manifest outputs
MUST NOT: Add runtime jargon to governance contracts
MUST: Ledger-consuming services declare source ledgers, scope filters, and closure gates
MUST: Learning governance remains live — closure claims require fresh DISCOVER → GENERATE → RELINK evidence
hadleylab-canonic
HADLEYLAB ships software. Every app, book, paper, deal, and patent is PROOF that MAGIC works. COIN = WORK. LEARNING = COMPUTE.
MUST: Every app, book, paper, deal, or patent is evidence of MAGIC
MUST: All scopes inherit canonic-canonic/CANONIC.md governance
MUST: All users governed under USERS/ via SERVICES/USER
MUST: Cross-index INTEL across users (INTEL.md)
MUST: Shared events propagate to ALL affected user dashboards
MUST: Maintain governance workspace purity (.md files only)
MUST: Ledger all COIN (validated work) through MAGIC 255
MUST: Compile all INTEL from governed sources
MUST: Keep frontend/runtime implementation under ~/.canonic (hidden runtime)
MUST: Surface governed TALK, Library, and SERVICES scopes (no orphan content)
MUST: Derive nav labels from governed scope names (no hardcoded strings)
MUST NOT: Publish without governance (CANON.md required)
MUST NOT: Duplicate primitives — compose from INTEL, CHAT, COIN
MUST NOT: Silo intelligence inside a single user when multiple are affected
MUST NOT: Expose VAULT contents outside NDA scope
MUST NOT: Store runtime artifacts in governance workspace
canonic-canonic
SPEC is governance. `canonic-canonic/` is the spec root.
MUST: Keep this repo governance-only (.md/.pdf)
MUST: Publish workspace mapping in CANONIC.git (no hardcoded repo lists)
MUST: Preserve three primary lanes: FOUNDATION, INDUSTRIES, MAGIC
MUST NOT: Commit runtime artifacts here (runtime belongs in ~/.canonic/)
MUST: Sell MAGIC tiers — the product, not the proof (proof is hadleylab-canonic)
MUST NOT: Embed beta-test app URLs in platform page content